Literature DB >> 11585054

Enhanced activity of antisense phosphorothioate oligos against leishmania amastigotes: augmented uptake of oligo, ribonuclease H activation, and efficient target intervention under altered growth conditions.

M Mishra1, J M Porter-Kelley, P K Singh, J R Bennett, G Chaudhuri.   

Abstract

Leishmania, a parasitic protozoan, infects human macrophages, often causing severe morbidity and mortality. The pathogenic form of this parasite, the amastigote, lives inside the acidic phagolysosomes of infected macrophages. In our attempt to develop anti-miniexon phosphorothioate oligodeoxyribonucleotides (S-oligos) as an alternative chemotherapy against Leishmania, we found that intracellular as well as 'axenic' amastigotes were more susceptible to these S-oligos than were the cultured promastigotes. Lower pH (4.5) and elevated temperature (35 degrees) of the medium were among the direct enhancing factors for killing. Addition of the cationic polypeptide poly-l-lysine (PLL) to the growth medium further enhanced the killing effect of the S-oligo at pH 4.5. The enhancement of specific ablation of mRNA expression was directly correlated to the increased leishmanicidal activity of the S-oligo. This was shown by the increased inhibition of luciferase activity expressed in transgenic Leishmania amazonensis promastigotes by anti-miniexon S-oligo or anti-luciferase S-oligo at acidic pHs and in the presence of PLL. The leishmanicidal effects of S-oligos at acidic pH and in the presence of PLL were related to increased uptake of the S-oligos under these conditions. The rate of S-oligo uptake was enhanced up to 15-fold at pH 4.5. The addition of PLL to the assay medium at acidic pH further enhanced the uptake of S-oligo up to 80-fold. RNase H is known to accentuate the antisense action of S-oligos. We found that at an elevated temperature RNase H activity in Leishmania cell extracts increased about 5-fold. Thus, enhanced uptake of S-oligos at the acidic pH of macrophage phagolysosomes and activation of RNase H may explain the efficient killing of the parasite in macrophages, both in tissue culture and in the animal model, by antisense miniexon oligonucleotide/PLL, when targeted directly to the parasite-containing phagolysosomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585054      PMCID: PMC3085994          DOI: 10.1016/s0006-2952(01)00695-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  39 in total

Review 1.  Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery.

Authors:  A Bochot; P Couvreur; E Fattal
Journal:  Prog Retin Eye Res       Date:  2000-03       Impact factor: 21.198

2.  Identification and characterization of a transcriptional silencer upstream of the human BRCA2 gene.

Authors:  C Sharan; N M Hamilton; A K Parl; P K Singh; G Chaudhuri
Journal:  Biochem Biophys Res Commun       Date:  1999-11-19       Impact factor: 3.575

3.  Human cutaneous lieshmania in a mouse macrophage line: propagation and isolation of intracellular parasites.

Authors:  K P Chang
Journal:  Science       Date:  1980-09-12       Impact factor: 47.728

Review 4.  Antisense oligonucleotides as therapeutic agents.

Authors:  U Galderisi; A Cascino; A Giordano
Journal:  J Cell Physiol       Date:  1999-11       Impact factor: 6.384

5.  Cationic liposome-encapsulated antisense oligonucleotide mediates efficient killing of intracellular Leishmania.

Authors:  R Chakraborty; D Dasgupta; S Adhya; M K Basu
Journal:  Biochem J       Date:  1999-06-01       Impact factor: 3.857

6.  Antisense effects of oligonucleotides complementary to the hairpin of the Leishmania mini-exon RNA.

Authors:  D Compagno; J J Toulmé
Journal:  Nucleosides Nucleotides       Date:  1999 Jun-Jul

7.  Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.

Authors:  T W Stone; G J Jaffe
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

8.  Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake.

Authors:  G Schmajuk; H Sierakowska; R Kole
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

9.  Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection.

Authors:  P C Cotrim; L K Garrity; S M Beverley
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

Review 10.  Leishmania species: models of intracellular parasitism.

Authors:  J Alexander; A R Satoskar; D G Russell
Journal:  J Cell Sci       Date:  1999-09       Impact factor: 5.285

View more
  5 in total

1.  Molecular characterization of a human BRCA2 homolog in Leishmania donovani.

Authors:  Smita Misra; Mack Hall; Gautam Chaudhuri
Journal:  J Parasitol       Date:  2005-12       Impact factor: 1.276

2.  Down-regulation of 7SL RNA expression and impairment of vesicular protein transport pathways by Leishmania infection of macrophages.

Authors:  Smita Misra; Manish K Tripathi; Gautam Chaudhuri
Journal:  J Biol Chem       Date:  2005-06-14       Impact factor: 5.157

3.  Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani.

Authors:  Puneet Raina; Sukhbir Kaur
Journal:  Mol Cell Biochem       Date:  2011-07-31       Impact factor: 3.396

4.  Leishmania-induced repression of selected non-coding RNA genes containing B-box element at their promoters in alternatively polarized M2 macrophages.

Authors:  Anitra L Farrow; Tanu Rana; Mukul K Mittal; Smita Misra; Gautam Chaudhuri
Journal:  Mol Cell Biochem       Date:  2010-12-17       Impact factor: 3.396

5.  A type II ribonuclease H from Leishmania mitochondria: an enzyme essential for the growth of the parasite.

Authors:  Smita Misra; Jabbar Bennett; Yeshitila N Friew; Junaid Abdulghani; Charletha V Irvin-Wilson; Manish K Tripathi; Shauntae Williams; Minu Chaudhuri; Gautam Chaudhuri
Journal:  Mol Biochem Parasitol       Date:  2005-10       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.